Filed with ASX · · 2 pages · English
The appointment secures essential clinical infrastructure and experienced personnel for the upcoming study, which aims to evaluate the safety and pharmacokinetics of a stable isotope-based imaging platform. Initial participant enrollment is targeted for the first quarter of the following year, with preliminary results expected shortly thereafter, pending regulatory approvals.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX ANNOUNCEMENT 11 November 2026 TrivarX Appoints Emeritus Research for Phase 1 Study • Emeritus Research formally engaged to conduct the planned Phase 1 healthy volunteer study of Stabl-Im at its Melbourne clinical research facility • Established Australian clinical research site brings over...
Follow TrivarX into a list and get an email when it puts out news.
Follow TrivarX